CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Jonathan Lim

Chairman, Chief Executive Officer and Co-Founder, Erasca, Inc.

Search every verified Jonathan Lim interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Jonathan Lim, Chairman, Chief Executive Officer and Co-Founder of Erasca, participated in a panel at the 2026 WMIF conference on September 23, 2026, titled "Unbreakable Tumors? Not Anymore | The Future of Solid Tumor Treatment." During the discussion, Lim cited the RAS oncogene as an example of a target once considered undruggable, attributing progress to novel allosteric approaches and covalent chemistry developed since 2013, which he said "cracked the nut" in the field. He also reflected on the role of human ingenuity in drug discovery, contrasting embodied human creativity with current machine capabilities, and commented on how the "favored nation" pricing policy in the U.S. may reshape commercialization strategies for small companies, suggesting that a U.S.-only business could become more viable.

Recent appearances

  • 2026 WMIF | Unbreakable Tumors? Not Anymore | The Future of Solid Tumor Treatment

    Summary Solid tumor treatment has progressed through successive waves of chemotherapy, targeted therapy, immunotherapy and increasingly precise approaches to previously difficult targets. Aamir Mecklai and Rebecca Heist MD joined Roy Baynes MD, PhD, Ryan Cohlhepp PharmD and Jonathan Lim MD to explore what is changing now. Baynes described a new phase of precision oncology enabled by better molecules, diagnostics, patient segmentation and trial design. Lim used RAS as an example of a target once considered undruggable that has opened through new chemistry, while emphasizing that the next gains…

    Watch on YouTube ↗

  • Biotech CEO on where we are in the fight to cure cancer

    Jonathan Lim is the CEO of Erasca, but his career path took him on a fascinating journey from practicing as a surgeon to leading life science companies. In a recent conversation, Lim shared valuable insights about his transition to the biotech world, his leadership experiences, and the lessons he's learned while founding and guiding organizations through high-stakes decision making. Reflecting on a personal trip to the Galapagos Islands, Lim also drew parallels between Darwinian evolution and business. In today’s challenging biotech environment, entrepreneurs need to adapt or die, consistent…

    Watch on YouTube ↗

  • 'My Penguin Friend': A Conversation with Jonathan Lim (Producer & Founder of City Hill Arts)

    Check out our review of 'My Penguin Friend' Here:    • My Penguin Friend – Christian Movie Review  . Timestamps: 0:00 Introduction 0:42 What Led You Into the Film Industry? 4:31 The Importance of Positive Human Stories 6:18 When did this true story first get on your radar? 8:12 Was it a real Penguin in the movie? 10:00 The performance of actor Jean Reno 12:26 What was the vision for this movie? 16:38 How did you faith influence this film? 19:33 What do you hope viewers will take away from this film? Make sure to subscribe to the channel, like the video, and jump into the comments sectio…

    Watch on YouTube ↗

  • Founder Stories: Jonathan Lim, Founder of Erasca and Ignyta

    Dr. Jonathan Lim is a physician-turned-venturepreneur at City Hill and ARCH Venture who founds, funds and leads mission-driven for-profit and non-profit ventures dedicated to revitalizing people, planet and perspective. Within the City Hill Ventures and ARCH portfolios, Dr. Lim serves as Chairman, CEO and Co-Founder of Erasca; Chairman and Co-Founder of Boundless Bio; and Board Director of Maze Therapeutics. From 2003 to 2018, Dr. Lim was a leader and founding investor of four biotech companies (Halozyme, Eclipse, Ignyta and Bonti) that have collectively delivered seven approved therapeutic pr…

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →